Premium
A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low‐Calorie Diet
Author(s) -
Shaw Tronieri Jena,
Wadden Thomas A.,
Berkowitz Robert I.,
Chao Ariana M.,
Pearl Rebecca L.,
Alamuddin Naji,
Leonard Sharon M.,
Carvajal Ray,
Bakizada Zayna M.,
Pinkasavage Emilie,
Gruber Kathryn A.,
Walsh Olivia A.,
Alfaris Nasreen
Publication year - 2018
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.22081
Subject(s) - weight loss , medicine , placebo , randomization , randomized controlled trial , calorie , obesity , physical therapy , alternative medicine , pathology
Objective Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long‐term behavioral and/or pharmacological interventions. Methods This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m 2 ) who had lost ≥ 5% of initial weight during a 14‐week low‐calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks. Results At 24 weeks post randomization, more lorcaserin‐treated than placebo‐treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin‐treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo ( P = 0.010). However, at week 52, groups did not differ on either co‐primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss ( P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg ( P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively ( P = 0.318). Conclusions Combined behavioral and pharmacological treatment produced clinically meaningful long‐term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.